NASDAQ:SCYX

SCYNEXIS Stock Forecast, Price & News

$8.05

-0.16 (-1.95 %)

(As of 04/13/2021 10:24 AM ET)

Add

Compare

Today's Range

$7.87

Now: $8.05▼

$8.12

50-Day Range

$7.25

MA: $8.28▼

$8.94

52-Week Range

$4.20

Now: $8.05▼

$10.50

Volume4,507 shs

Average Volume639,649 shs

Market Capitalization$166.02 million

P/E RatioN/A

Dividend YieldN/A

Beta2.16

SCYNEXIS, Inc., a biotechnology company, delivers therapies for the treatment fungal infections in the United States. It is developing its lead product candidate, ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company develops ibrexafungerp, which has completed Phase II clinical trials for the treatment of vulvovaginal candidiasis. It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:SCYX

Previous Symbol

CUSIPN/A

CIK1178253

Webwww.scynexis.com

Phone201-884-5485

Employees38

Year FoundedN/A

Debt

Debt-to-Equity Ratio1.39

Current Ratio3.89

Quick Ratio3.89

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$120,000.00

Price / Sales1,383.46

Cash FlowN/A

Price / Cash FlowN/A

Book Value$1.32 per share

Price / Book6.10

Profitability

EPS (Most Recent Fiscal Year)($8.10)

Net Income$-53,710,000.00

Net MarginsN/A

Return on Equity-330.82%

Return on Assets-64.53%

Miscellaneous

Outstanding Shares20,623,000

Market Cap$166.02 million

Next Earnings Date5/10/2021 (Estimated)

OptionableOptionable

Headlines

SCYNEXIS (NASDAQ:SCYX) Has Debt But No Earnings; Should You Worry? - Yahoo Finance
April 13, 2021 | finance.yahoo.com

SCYNEXIS (NASDAQ:SCYX) Has Debt But No Earnings; Should You Worry?
April 12, 2021 | finance.yahoo.com

SCYNEXIS (NASDAQ:SCYX) Price Target Lowered to $40.00 at Aegis
April 12, 2021 | americanbankingnews.com

SCYNEXIS, Inc. (NASDAQ:SCYX) Expected to Earn FY2021 Earnings of ($3.21) Per Share
April 1, 2021 | americanbankingnews.com

SCYNEXIS (NASDAQ:SCYX) Posts Earnings Results, Misses Expectations By $2.80 EPS
March 30, 2021 | americanbankingnews.com

SCYNEXIS Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update - Yahoo Finance
March 29, 2021 | finance.yahoo.com

SCYNEXIS Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
March 29, 2021 | finance.yahoo.com

SCYNEXIS Stock Is Estimated To Be Significantly Overvalued
March 29, 2021 | finance.yahoo.com

Brokerages Anticipate SCYNEXIS, Inc. (NASDAQ:SCYX) Will Post Earnings of -$0.78 Per Share
March 28, 2021 | americanbankingnews.com

Scynexis (SCYX) Announces Positive Results from Interim Analyses of Ongoing Phase 3 Studies (FURI and CARES), Demonstrating Oral Ibrexafungerp's Ability to Treat Severe Fungal Infections in the Hospit - StreetInsider.com
March 2, 2021 | streetinsider.com

Scynexis' oral ibrexafungerp shows positive effect in fungal infections - Seeking Alpha
March 2, 2021 | seekingalpha.com

SCYNEXIS Announces Positive Results from Interim Analyses of Ongoing Phase 3 Studies (FURI and CARES), Demonstrating Oral Ibrexafungerp's Ability to Treat Severe Fungal Infections in the Hospital Setting - GlobeNewswire
March 2, 2021 | globenewswire.com

SCYNEXIS to Participate in Maxim Group’s Late Stage Innovations in Women’s Health Virtual Event - Yahoo Finance
February 25, 2021 | finance.yahoo.com

SCYNEXIS to Participate in Maxim Group's Late Stage Innovations in Women's Health Virtual Event - GlobeNewswire
February 25, 2021 | globenewswire.com

SCYNEXIS to Participate in Maxim Group’s Late Stage Innovations in Women’s Health Virtual Event
February 25, 2021 | finance.yahoo.com

SCYNEXIS (SCYX) and Amplity Health Announce Agreement to Support the Anticipated US Commercialization of BrexafemmeTM (Ibrexafungerp) for Vaginal Yeast Infections - StreetInsider.com
February 23, 2021 | streetinsider.com

Form 8-K SCYNEXIS INC For: Feb 19 - StreetInsider.com
February 23, 2021 | streetinsider.com

SCYNEXIS and Amplity Health Announce Agreement to Support the Anticipated U.S. Commercialization of BrexafemmeTM (Ibrexafungerp) for Vaginal Yeast Infections - GlobeNewswire
February 23, 2021 | globenewswire.com

SCYNEXIS and Hansoh Pharma ink license deal for - Seeking Alpha
February 17, 2021 | seekingalpha.com

See More Headlines

MarketRank^™

Overall MarketRank^™

1.43 out of 5 stars

Medical Sector

614th out of 2,016 stocks

Pharmaceutical Preparations Industry

284th out of 771 stocks

3.5 Analyst's Opinion

Consensus Rating
SCYNEXIS has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $30.29, SCYNEXIS has a forecasted upside of 279.5% from its current price of $7.98.
Amount of Analyst Coverage
SCYNEXIS has only been the subject of 3 research reports in the past 90 days.

2.8 Community Rank

Outperform Votes
SCYNEXIS has received 486 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
SCYNEXIS has received 385 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
SCYNEXIS has received 55.80% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about SCYNEXIS and other stocks. Vote “Outperform” if you believe SCYX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SCYX will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
SCYNEXIS does not currently pay a dividend.
Dividend Growth
SCYNEXIS does not have a long track record of dividend growth.

0.8 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, SCYNEXIS insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,003,110.00 in company stock.
Percentage Held by Insiders
Only 4.06% of the stock of SCYNEXIS is held by insiders.
Percentage Held by Institutions
36.92% of the stock of SCYNEXIS is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0 Earnings and Valuation

Earnings Growth
Earnings for SCYNEXIS are expected to decrease in the coming year, from ($2.77) to ($2.81) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of SCYNEXIS is -2.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of SCYNEXIS is -2.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
SCYNEXIS has a P/B Ratio of 6.05. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

$8.05

-0.16 (-1.95 %)

(As of 04/13/2021 10:24 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive SCYX News and Ratings via Email

Sign-up to receive the latest news and ratings for SCYX and its competitors with MarketBeat's FREE daily newsletter.

SCYNEXIS (NASDAQ:SCYX) Frequently Asked Questions

Is SCYNEXIS a buy right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for SCYNEXIS in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SCYNEXIS stock.
View analyst ratings for SCYNEXIS or view top-rated stocks.

What stocks does MarketBeat like better than SCYNEXIS?

Wall Street analysts have given SCYNEXIS a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but SCYNEXIS wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting SCYNEXIS?

SCYNEXIS saw a increase in short interest in the month of February. As of February 26th, there was short interest totaling 1,110,000 shares, an increase of 40.6% from the February 11th total of 789,300 shares. Based on an average daily trading volume, of 672,100 shares, the days-to-cover ratio is presently 1.7 days. Currently, 6.0% of the company's shares are short sold.
View SCYNEXIS's Short Interest.

When is SCYNEXIS's next earnings date?

SCYNEXIS is scheduled to release its next quarterly earnings announcement on Monday, May 10th 2021.
View our earnings forecast for SCYNEXIS.

How were SCYNEXIS's earnings last quarter?

SCYNEXIS, Inc. (NASDAQ:SCYX) issued its quarterly earnings data on Sunday, March, 28th. The company reported ($3.53) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.73) by $2.80.
View SCYNEXIS's earnings history.

How has SCYNEXIS's stock been impacted by COVID-19?

SCYNEXIS's stock was trading at $7.8020 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, SCYX shares have increased by 3.2% and is now trading at $8.05.
View which stocks have been most impacted by COVID-19.

When did SCYNEXIS's stock split? How did SCYNEXIS's stock split work?

SCYNEXIS shares reverse split on the morning of Friday, July 17th 2020. The 1-10 reverse split was announced on Thursday, July 16th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, July 16th 2020. An investor that had 100 shares of SCYNEXIS stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for SCYX?

7 brokerages have issued twelve-month price targets for SCYNEXIS's stock. Their forecasts range from $20.00 to $50.00. On average, they anticipate SCYNEXIS's stock price to reach $30.29 in the next twelve months. This suggests a possible upside of 276.2% from the stock's current price.
View analysts' price targets for SCYNEXIS or view top-rated stocks among Wall Street analysts.

Who are SCYNEXIS's key executives?

SCYNEXIS's management team includes the following people:

Dr. Marco Taglietti, CEO, Pres & Director (Age 61, Pay $937.35k)
Mr. Eric Francois, Chief Financial Officer (Age 46, Pay $604.91k)
Mr. David Gonzalez Angulo, Chief Medical Officer (Age 56, Pay $676.13k)
Mr. Scott Sukenick J.D., Gen. Counsel & Corp. Sec. (Age 43)
Mr. Jim Maffezzoli, VP of Marketing & Sales
Dr. Rajeshwar Motheram, Sr. VP of Pharmaceutical Devel. & Supply Chain

Who are some of SCYNEXIS's key competitors?

Some companies that are related to SCYNEXIS include Emisphere Technologies (EMIS), Clovis Oncology (CLVS), OrganiGram (OGI), Gossamer Bio (GOSS), Kadmon (KDMN), Evelo Biosciences (EVLO), Xenon Pharmaceuticals (XENE), Bicycle Therapeutics (BCYC), KalVista Pharmaceuticals (KALV), Albireo Pharma (ALBO), Relmada Therapeutics (RLMD), Chinook Therapeutics (KDNY), Magenta Therapeutics (MGTA), IDEAYA Biosciences (IDYA) and Crinetics Pharmaceuticals (CRNX).
View all of SCYX's competitors.

What other stocks do shareholders of SCYNEXIS own?

Based on aggregate information from My MarketBeat watchlists, some companies that other SCYNEXIS investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Sorrento Therapeutics (SRNE), Gran Tierra Energy (GTE), KushCo (KSHB), Zosano Pharma (ZSAN), Bionano Genomics (BNGO), Outlook Therapeutics (OTLK), Cogent Biosciences (UMRX) and Aeterna Zentaris (AEZS).

What is SCYNEXIS's stock symbol?

SCYNEXIS trades on the NASDAQ under the ticker symbol "SCYX."

How do I buy shares of SCYNEXIS?

Shares of SCYX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is SCYNEXIS's stock price today?

One share of SCYX stock can currently be purchased for approximately $8.05.

How much money does SCYNEXIS make?

SCYNEXIS has a market capitalization of $166.02 million and generates $120,000.00 in revenue each year. The company earns $-53,710,000.00 in net income (profit) each year or ($8.10) on an earnings per share basis.

How many employees does SCYNEXIS have?

SCYNEXIS employs 38 workers across the globe.

What is SCYNEXIS's official website?

The official website for SCYNEXIS is www.scynexis.com.

Where are SCYNEXIS's headquarters?

SCYNEXIS is headquartered at 1 EVERTRUST PLAZA 13TH FLOOR, JERSEY CITY NJ, 07302.

How can I contact SCYNEXIS?

SCYNEXIS's mailing address is 1 EVERTRUST PLAZA 13TH FLOOR, JERSEY CITY NJ, 07302. The company can be reached via phone at 201-884-5485 or via email at [email protected]

This page was last updated on 4/13/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here